GLP-1Rs are expressed in the pancreas, intestinal intraepithelial lymphocytes, myocardium, adipose tissue, kidney, liver, blood vessels, lungs and in the CNS.2,3 Although GLP-1 is known for its incretin effect, which it shares with glucose-dependent insulinotropic peptide (GIP), the intake-regulating action, essential for its efficacy against obesity, occurs through its interaction with receptors located in the CNS.1,5 The GLP-1 peptide can reach the central nervous system (CNS) via peripheral vagal afferents, which transmit its action through the nodose ganglion to the nucleus tactus solitarius (NTS)
But as their use has expanded, an important concern has emerged: not all of the weight being lost is fat
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
CrossRef Zheng X, Wang H, Liu P, et al
As of Oct